Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution

Stock Information for Appili Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Appili Therapeutics Inc

Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
OTCQB Venture Virtual Investor Conference Presentations Now Available for On-Demand Viewing
OTCQB Venture Virtual Investor Conference Agenda Announced for August 1st
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.